吲哚布芬在短暂性脑缺血发作治疗中的临床疗效观察  

Observation on clinical efficacy of indobufen in the treatment of transient ischemic attack

作　　者：李斌 LI Bin(Department of Pharmacy,Wuzhou Red Cross Hospital,Wuzhou 543000,China)

机构地区：[1]梧州市红十字会医院药学部,543000

出　　处：《中国现代药物应用》2025年第3期77-80,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨吲哚布芬治疗短暂性脑缺血发作患者的临床疗效及对其血液流变学的影响。方法120例短暂性脑缺血发作患者,随机分为对照组和治疗组,每组60例。对照组采取常规治疗,治疗组在对照组基础上采取吲哚布芬治疗。比较两组的临床疗效、不良反应发生情况及治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、日常生活活动能力量表(ADL)评分、血液流变学指标(血细胞比容、全血高切粘度、红细胞聚集指数、纤维蛋白原、红细胞沉降率)、血管活性因子[内皮素-1(ET-1)、血管性假血友病因子(vWF)、可溶性血管细胞粘附分子-1(sVCAM-1)、可溶性细胞间粘附分子-1(sICAM-1)]水平。结果治疗组总有效率为98.33%,高于对照组的88.33%,差异有统计学意义(P<0.05)。治疗后,两组的NIHSS评分较本组治疗前降低,ADL评分较本组治疗前升高,且治疗组的NIHSS评分(7.43±3.54)分低于对照组的(14.79±6.44)分,ADL评分(79.63±10.65)分高于对照组的(68.52±10.64)分,差异均有统计学意义(P<0.05)。治疗后,两组的血细胞比容、全血高切粘度、红细胞聚集指数、红细胞沉降率、纤维蛋白原均较本组治疗前明显降低,且治疗组的血细胞比容(37.24±4.15)%、全血高切粘度(3.48±0.36)mPa·s、红细胞聚集指数(4.17±0.69)、红细胞沉降率(22.34±2.34)mm/h、纤维蛋白原(2.64±0.84)g/L低于对照组的(39.45±3.68)%、(3.83±0.56)mPa·s、(4.45±0.64)、(23.46±3.34)mm/h、(3.02±0.75)g/L,差异具有统计学意义(P<0.05)。治疗后,治疗组的vWF、ET-1、sICAM-1、sVCAM-1水平及对照组的vWF、ET-1水平较本组治疗前均降低,且治疗组的vWF(111.56±29.63)%、ET-1(55.14±11.32)ng/L、sICAM-1(269.36±31.62)ng/ml、sVCAM-1(406.28±35.73)ng/ml均低于对照组的(156.35±28.82)%、(79.73±12.62)ng/L、(313.65±39.54)ng/ml、(463.16±32.42)ng/ml,差异有统计学意义(P<0.05)。两组治疗前后基础安全指标(血常规、肝肾功能指标)均Objective To explore the clinical efficacy of indobufen in the treatment of patients with transient ischemic attack,and its influence on hemorheology.Methods A total of 120 patients with transient ischemic attack were randomly divided into control group and treatment group,each with 60 cases.The control group received conventional treatment,and the treatment group received indobufen treatment on the basis of the control group.Comparison was made on clinical efficacy,occurrence of adverse reactions,National Institutes of Health Stroke Scale(NIHSS)score,Activities of Daily Living Scale(ADL)score,hemorheology index(hematocrit,whole blood high-shear viscosity,erythrocyte aggregation index,fibrinogen,erythrocyte sedimentation rate),vasoactive factor[endothelin-1(ET-1),Von Willebrand factor(vWF),soluble vascular cell adhesion molecule-1(sVCAM-1),soluble intercellular adhesion molecule-1(sICAM-1)]between the two groups.Results The total effective rate of the treatment group was 98.33%,which was higher than 88.33%of the control group,and the difference was statistically significant(P<0.05).After treatment,the NIHSS score in both groups was lower than that before treatment,and the ADL score was higher than that before treatment;the treatment group had lower NIHSS score of(7.43±3.54)points than(14.79±6.44)points in the control group,and higher ADL score of(79.63±10.65)points than(68.52±10.64)points in the control group;the differences were statistically significant(P<0.05).After treatment,the hematocrit,whole blood high-shear viscosity,erythrocyte aggregation index,erythrocyte sedimentation rate,fibrinogen in both groups were significantly lower than those before treatment;in the treatment group,the hematocrit was(37.24±4.15)%,the whole blood high-shear viscosity was(3.48±0.36)mPa·s,the erythrocyte aggregation index was(4.17±0.69),the erythrocyte sedimentation rate was(22.34±2.34)mm/h,and the fibrinogen was(2.64±0.84)g/L,which were lower than(39.45±3.68)%,(3.83±0.56)mPa·s,(4.45±0.64),(23.46±3.34)mm/h,and(3.0

关 键 词：吲哚布芬 短暂性脑缺血发作 临床疗效 血液流变学 

分 类 号：R743.31[医药卫生—神经病学与精神病学]